Alessandra Vergori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/930299/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 135-142.	0.6	0
2	Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH. Journal of Clinical Medicine, 2022, 11, 1546.	1.0	8
3	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clinical Infectious Diseases, 2022, 75. e552-e563.	2.9	79
4	Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV. Viruses, 2022, 14, 970.	1.5	3
5	COVIDâ€19 in people living with HIV: Clinical implications of dynamics of the immune response to SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1796-1804.	2.5	38
6	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clinical Microbiology and Infection, 2021, 27, 286.e7-286.e13.	2.8	104
7	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	1.8	87
8	Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients. Annals of Medicine, 2021, 53, 295-301.	1.5	33
9	Virological response and resistance profile in highly treatmentâ€experienced HIVâ€1â€infected patients switching to dolutegravir plus boosted darunavir in clinical practice. HIV Medicine, 2021, 22, 519-525.	1.0	6
10	Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. Journal of Antimicrobial Chemotherapy, 2021, 76, 1277-1285.	1.3	14
11	No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. Frontiers in Pharmacology, 2021, 12, 621676.	1.6	6
12	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. Journal of Infection, 2021, 82, 58-66.	1.7	44
13	High Levels of TRIM5α Are Associated with Xenophagy in HIV-1-Infected Long-Term Nonprogressors. Cells, 2021, 10, 1207.	1.8	6
14	Human immunodeficiency virus (HIV) and coronavirus disease 2019; impact on vulnerable populations and harnessing lessons learnt from HIV programmes. New Microbes and New Infections, 2021, 41, 100857.	0.8	3
15	Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. Scientific Reports, 2021, 11, 11334.	1.6	2
16	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. Arab Journal of Gastroenterology, 2021, 22, 75-87.	0.4	2
17	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Frontiers in Medicine, 2021, 8, 639970.	1.2	20
18	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10	1.1	2

ALESSANDRA VERGORI

#	Article	IF	CITATIONS
19	The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. International Journal of Molecular Sciences, 2021, 22, 7942.	1.8	20
20	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. Journal of Antimicrobial Chemotherapy, 2021, 76, 3272-3279.	1.3	0
21	Management of Spontaneous Bleeding in COVID-19 Inpatients: Is Embolization Always Needed?. Journal of Clinical Medicine, 2021, 10, 4119.	1.0	13
22	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. Nutrients, 2021, 13, 3571.	1.7	2
23	HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. Open Forum Infectious Diseases, 2021, 8, ofaa566.	0.4	2
24	SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series. International Journal of Infectious Diseases, 2020, 101, 38-41.	1.5	4
25	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load â‰ 9 0 copies/mL: does estimated glomerular filtration rate matter?. International Journal of Antimicrobial Agents, 2020, 56, 106154.	1.1	1
26	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. Journal of Clinical Virology, 2020, 130, 104534.	1.6	11
27	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	1.1	137
28	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. European Journal of Internal Medicine, 2020, 82, 38-47.	1.0	88
29	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The "STORE―Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 290-294.	0.9	3
30	Persistent gamma delta Tâ€cell dysfunction in HCV/HIV coâ€infection despite directâ€acting antiviral therapyâ€induced cure. Journal of Viral Hepatitis, 2020, 27, 754-756.	1.0	2
31	HIV MDR is still a relevant issue despite its dramatic drop over the years. Journal of Antimicrobial Chemotherapy, 2020, 75, 1301-1310.	1.3	13
32	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular Pharmacology, 2020, 135, 106805.	1.0	39
33	Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. Infezioni in Medicina, 2020, 28, 576-586.	0.7	Ο
34	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. Journal of Antimicrobial Chemotherapy, 2019, 74, 3295-3304.	1.3	14
35	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	1.2	46
36	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 1363-1367.	1.3	21

#	Article	IF	CITATIONS
37	Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects. Infection, 2019, 47, 929-935.	2.3	6
38	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. Sexually Transmitted Infections, 2019, 95, 619-625.	0.8	18
39	Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. International Journal of Antimicrobial Agents, 2019, 53, 515-519.	1.1	26
40	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaA⁻ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. HIV Medicine, 2019, 20, 99-109.	1.0	19
41	Gender differences in the use of cardiovascular interventions in <scp>HIV</scp> â€positive persons; the D:A:D Study. Journal of the International AIDS Society, 2018, 21, e25083.	1.2	10
42	Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence. Scientific Reports, 2018, 8, 15739.	1.6	2
43	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	1.3	8
44	Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals. HIV Medicine, 2018, 19, 578-584.	1.0	13
45	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine, 2018, 16, 79.	2.3	24
46	Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site. BMC Infectious Diseases, 2018, 18, 25.	1.3	18
47	Prevalence and clinical outcome of hepatitis Delta infection in patients with HIV/HBV coinfection. Journal of Hepatology, 2018, 68, S493.	1.8	0
48	Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC Infectious Diseases, 2017, 17, 182.	1.3	25
49	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14. Journal of Antimicrobial Chemotherapy, 2017, 72, 2837-2845.	1.3	15
50	Lower proportion of sustained virologic response and higher residual HCV viremia at the end of direct-acting antivirals treatment in HIV/HCV co-infected as compared with HCV mono-infected patients: meaning and correlates. Journal of Hepatology, 2017, 66, S510.	1.8	1
51	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. Journal of Clinical Microbiology, 2017, 55, 2827-2837.	1.8	18
52	Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. PLoS ONE, 2017, 12, e0187095.	1.1	14
53	Listeria meningoencephalitis and anti-GQ1b antibody syndrome. Infection, 2016, 44, 543-546.	2.3	6
54	Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature. IDCases, 2015, 2, 109-115.	0.4	16

#	Article	IF	CITATIONS
55	Hepatic Kaposi's sarcoma in a patient affected by AIDS: Correlation between histology and imaging. Journal of Ultrasound, 2012, 15, 215-219.	0.7	16